Vanguard Capital Management
BTAI icon

Vanguard Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Vanguard Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
919,545
+712,206
+343% +$834K ﹤0.01% 3536
2026
Q1 		$278K Buy
+207,339
New +$341K ﹤0.01% 3761

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
P
&Partners Nashville, Tennessee $24.4B AUM 27.45% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management's BTAI Position: Q2 2026 in Review

Vanguard Capital Management increased its BioXcel Therapeutics (BTAI) stake by 343% in Q2 2026, buying an estimated $834K and bringing the position to 919,545 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3536.

Vanguard Capital Management first reported a position in BTAI in Q1 2026 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Vanguard Capital Management held 919,545 shares of BioXcel Therapeutics worth $1.3M as of Q2 2026.
  • Vanguard Capital Management bought 712,206 BioXcel Therapeutics shares in Q2 2026, an estimated $834K.
  • BioXcel Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3536 holding.
  • Vanguard Capital Management first reported a position in BioXcel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.